ACCESS Newswire·Aug 4, 2026, 4:05 PM ET

Protagonist Therapeutics Reports Granting of Inducement Awards

Protagonist Therapeutics granted inducement awards on July 31, 2026, to two recently hired employees under its Amended and Restated Inducement Plan.
The awards consist of 7,300 stock options & 1,975 restricted stock units (RSUs) in the aggregate.
The option exercise price is $136.64 per share, matching the closing price on the Nasdaq Global Market on the grant date.
Stock options vest over four years with 25% vesting on the first anniversary & the remainder vesting in equal monthly installments thereafter.
RSUs vest one-fourth annually over a four-year period.
The awards were approved by the compensation committee as a material inducement in compliance with Nasdaq Marketplace Rule 5635(c)(4).
ICOTYDE launched in the U.S. in March 2026 for moderate-to-severe plaque psoriasis & is in Phase 3 development for psoriatic arthritis, ulcerative colitis, & Crohn's disease.
The NDA for rusfertide, a hepcidin mimetic peptide, is under priority review with the FDA for polycythemia vera.
The company maintains additional clinical & preclinical programs including oral IL-17 antagonists, obesity agonists, & recently announced IL-4 & amylin programs.